Vials

Ipamorelin 10mg

Name: Ipamorelin 10mg
Brand: Quanta Pharmaceuticals

A selective GHRP pentapeptide studied for growth hormone release with minimal cortisol or appetite effects.

Ipamorelin is a pentapeptide ghrelin mimetic in the GHRP (growth hormone releasing peptide) class, studied for stimulating growth hormone release via the ghrelin receptor (GHS-R1a). It is frequently paired with a GHRH analogue such as CJC-1295 in research protocols targeting amplified GH release. The original 1998 characterisation study (Raun et al.) described it as the first GHRP-class secretagogue with GH selectivity comparable to GHRH itself: ACTH and cortisol were not significantly elevated even at doses over 200 times the amount needed for half-maximal GH release, and prolactin, FSH, LH, and TSH were unaffected — a selectivity profile that set it apart from earlier-generation GHRPs like GHRP-6. Each vial is supplied at 10mg.

Verify a product

Independent laboratory documentation

Certificates of Analysis

View the laboratory reports currently published for this product.

Certificate of Analysis

View page 1 View page 2

Specifications

Peptide

Ipamorelin

Class

GHRP (Ghrelin Mimetic)

Dosage

10mg/vial

Half-Life

~2 hours

Administration

Injectable

Form

Lyophilised

Research Benefits

Selective GH release — The founding 1998 study found no significant cortisol or ACTH elevation even at 200x the GH-releasing dose.
No effect on other pituitary hormones — Prolactin, FSH, LH, and TSH remain unaffected, unlike earlier GHRPs such as GHRP-6.
GHRH stack synergy — Frequently paired with GHRH analogues like CJC-1295, which act on a separate receptor to amplify GH release.
Muscle preservation research — Investigated in body-composition and anti-ageing protocols.

How It Works

Ipamorelin is a pentapeptide that mimics the endogenous hormone ghrelin at the GHS-R1a receptor in the pituitary and hypothalamus, triggering the release of growth hormone. The peptide's founding pharmacology study demonstrated that this GH-releasing effect occurs largely in isolation from other pituitary hormones, distinguishing it from earlier GHRPs which reliably raised cortisol and prolactin alongside GH.

Because it acts on a different receptor than GHRH analogues (which act on the GHRH receptor rather than the ghrelin receptor), Ipamorelin is commonly studied in combination with compounds like CJC-1295, where the two pathways are thought to produce a larger GH pulse together than either alone.

⚠ For Research Use Only

This product is supplied strictly for in-vitro laboratory and preclinical research use. It is not a drug, food, dietary supplement, or cosmetic, and is not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease. Ipamorelin 10mg must be handled only by qualified individuals trained in proper laboratory safety procedures.

By purchasing, the buyer confirms this product is being acquired for legitimate research purposes and assumes full responsibility for its handling, storage, and use in compliance with all applicable local, national, and international laws.